Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorder treatments, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The management team will deliver a presentation on Wednesday, December 4, 2024, at 2:30pm Eastern Time. The presentation will be accessible via live audio webcast through the investor relations section of Neuronetics' website at ir.neuronetics.com.
Neuronetics (NASDAQ: STIM), un'azienda di tecnologia medica specializzata nel trattamento dei disturbi della salute neuropsichica, ha annunciato la sua partecipazione alla 36ª Conferenza Sanitaria Annuale di Piper Sandler. Il team di gestione presenterà un intervento mercoledì 4 dicembre 2024, alle 14:30 ora orientale. La presentazione sarà disponibile in diretta audio tramite webcast nella sezione relazioni con gli investitori del sito web di Neuronetics su ir.neuronetics.com.
Neuronetics (NASDAQ: STIM), una empresa de tecnología médica especializada en tratamientos de trastornos de la neurosalud, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El equipo de gestión realizará una presentación el miércoles 4 de diciembre de 2024, a las 2:30 p.m. hora del este. La presentación estará disponible a través de una transmisión de audio en vivo en la sección de relaciones con los inversores del sitio web de Neuronetics en ir.neuronetics.com.
Neuronetics (NASDAQ: STIM)는 신경 건강 장애 치료를 전문으로 하는 의료 기술 회사로, 파이퍼 샌들러 제36회 연례 의료 회의에 참석한다고 발표했습니다. 경영진 팀은 2024년 12월 4일 수요일 오후 2시 30분 동부 표준시에 발표를 할 예정입니다. 발표는 Neuronetics 웹사이트의 투자자 관계 섹션을 통해 실시간 오디오 웹캐스트로 이용할 수 있습니다. ir.neuronetics.com에서 확인하실 수 있습니다.
Neuronetics (NASDAQ: STIM), une entreprise de technologie médicale spécialisée dans le traitement des troubles de la santé neuropsychique, a annoncé sa participation à la 36e Conférence Annuelle de Santé de Piper Sandler. L'équipe de direction fera une présentation le mercredi 4 décembre 2024, à 14h30, heure de l'Est. La présentation sera accessible via un webinaire audio en direct dans la section des relations investisseur du site web de Neuronetics à l'adresse ir.neuronetics.com.
Neuronetics (NASDAQ: STIM), ein Medizintechnikunternehmen, das sich auf die Behandlung von Neurogesundheitsstörungen spezialisiert hat, hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. Das Managementteam wird am Mittwoch, den 4. Dezember 2024, um 14:30 Uhr Eastern Time eine Präsentation halten. Die Präsentation wird live über ein Audio-Webcast im Investor Relations-Bereich der Neuronetics-Website unter ir.neuronetics.com verfügbar sein.
- None.
- None.
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast.
A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration (the “FDA”) for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When is Neuronetics (STIM) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Neuronetics' (STIM) presentation at the Piper Sandler Conference?
Which healthcare conference is Neuronetics (STIM) participating in December 2024?
